CD70 and Miyoshi myopathy: Similarly, the role of CD70 in promoting lymphocyte proliferation and its selective overexpression in high-risk MM subtypes, such as extramedullary disease, positions it as a strong candidate for both CAR-T and antibody-based therapies, with additional potential for combination strategies aimed at reducing immune evasion through CD27 signaling modulation [32, 34].